---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-060904"
form_type: "8-K"
ticker: "BRVE"
cik: "0002131524"
company_name: "Braveheart Bio, Inc."
filed_at: "2026-09-08T20:06:55+00:00"
generated_at: "2026-09-08T20:08:10.215688+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing

## Summary
- Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.
- Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.
- LIONHEART-HCM Phase 3 for oHCM initiated; first patient dosing expected 2026, interim results 2H 2027.
- NOBLEHEART-HCM Phase 3 in nHCM expected to start 1H 2027 after Q2 Phase 2 data presented at HFA-ESC 2026.
- R&D expense $11.1M (vs $0.0M), G&A $4.8M (vs <$0.1M) on advancement and public-company prep.

## SEC filing metadata
- accession: 0001628280-26-060904
- form_type: 8-K
- ticker: BRVE
- cik: 0002131524
- company_name: Braveheart Bio, Inc.
- filed_at: 2026-09-08T20:06:55+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/0001628280-26-060904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/bhb-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-060904
- JSON: https://secwatch.observer/filing/0001628280-26-060904.json
- Plain text: https://secwatch.observer/filing/0001628280-26-060904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.